Back to results
US 12,377,077 B2Granted
Methods and formulations to treat mitochondrial dysfunction
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsTereza Moore, Tina M. Cowan, Gregory M. Enns, Mehrdad Shamloo, Michael J. Green, Alam Jahangir, Rolando E. Yanes
Life of this patent
Estimating the term…
Abstract
Methods of treatment and pharmaceutical formulations configured to treat primary and secondary mitochondrial dysfunction are provided. The methods and treatments use an agonist of AMPK. The agonist activates AMPK to activate ATP-producing pathways and inhibiting ATP-consuming pathways, thus allowing for the alleviation of symptoms associated with mitochondrial dysfunctions.
Claims17
A compound of formula:
- wherein:
- A is selected from
- X is CR5 or N;
- R1 is H, CF3, or halo;
- R2 is OR5, NHOH, NHSO2R4, or OCH2OCOR4, or COR2 is a C-linked tetrazole,
- R3 is C1-10 alkyl, C3-7 cycloalkyl, C4-12 alkylcycloalkyl, C4-10 cycloalkylalkyl, C3-7 heterocycloalkyl, C4-12 alkylheterocycloalkyl, C4-10 heterocycloalkylalkyl, aryl or heteroaryl either unsubstituted or substituted with one to three substituents selected from halo, OH and OCOR7;
- R4 is C1-10 alkyl, C3-7 cycloalkyl, C4-12 alkylcycloalkyl, C4-10 cycloalkylalkyl either unsubstituted or substituted with one to three halogen substituents;
- R5 is R4 or H;
- R6 is H, C1-6 alkyl, C3-6 cycloalkyl, or two R6 groups, together with the nitrogen atom to which they are attached can form a four to seven membered heterocycloalkyl ring, all of which can be optionally substituted with 1 to 3 fluorine atoms;
- and
- R7 is C1-10 alkyl, C3-7 cycloalkyl, C4-12 alkylcycloalkyl unsubstituted or substituted with one to three substituents selected from fluoro, C1-10 alkyl, and NR6R6.
8 more elements
Dependencies are inferred from the claim text.